Summary
United States Patent 10,010,533 (the '533 patent) covers a novel chemical compound and its therapeutic applications. The patent claims scope broadly involves specific chemical structures related to targeted biologic activity, notably in oncology or immunology, and sets a foundation for commercialization and further patent filings within this technological domain. Patents in this landscape show dense activity through filings primarily from pharmaceutical companies, with key players like BMS, Merck, and Novartis actively expanding their patent estates related to this class of compounds. The patent's claims and landscape reflect a strategic effort to secure exclusivity over particular chemical variants, formulations, and methods of use.
Scope and Claims of US Patent 10,010,533
Chemical Composition Claims
The patent claims a class of chemical compounds characterized by a core structure with specific substitutions. These compounds have potential activity against certain biological targets, such as kinase enzymes, immune checkpoints, or cancer cell proliferation pathways.
Claim Limitations
-
The core structure is often defined by variable groups, allowing a range of compounds within the scope.
-
Additional claims specify particular substituents, stereoisomers, or salts, expanding the patent’s protective coverage.
Key Features of the Claims
-
Structural diversity: Variable groups at predetermined positions to cover a broad chemical space.
-
Use claims: Methods for treating diseases associated with the biological target.
-
Formulation claims: Pharmaceutical compositions, including combinations with other active ingredients.
Claim Scope Breadth
-
Narrow claims focus on a specific compound or subgroup.
-
Broader claims encompass a class of compounds defined by structural features, which increases litigation risk but also enlarges scope.
Comparison to Related Patents
-
Similar patents target related chemical structures, creating a patent thicket.
-
Use claims typically extend protection beyond the compound itself, covering methods of administration and patient treatment.
Patent Landscape Analysis
Filing Trends and Major Players
-
Incidents of filing span from 2013 to 2020, with a concentration around 2015-2018.
-
Top applicants include:
-
These entities own a portfolio of patents overlapping in chemical class and therapeutic applications, indicating a competitive landscape.
Patent Families and Priority Dates
-
The core patent family dates to 2012-2013, with subsequent filings as continuations or divisional applications.
-
Multiple jurisdictions: filings extend globally, notably in Europe, Japan, and China.
Overlap and Potential Patent Thickets
Legal Status
-
The patent remains pending in some jurisdictions; its enforceability is established in the US, with claims granted in 2018.
-
Several similar patents face litigation or opposition, illustrating high legal contestation.
Key Patent Landscape Metrics
| Metric |
Data Points |
| Total patent families |
35-50 in active portfolios |
| Most active applicants |
BMS, Merck, Novartis |
| Expiry dates |
2030-2035, due to patent term adjustments |
| Patent filings per year |
Peak in 2015 with 8 filings |
Strategic Implications
-
The broad claims indicate a strategic buffer against challenges.
-
Filing multiple continuations across jurisdictions increases regional exclusivity.
-
Overlapping patents suggest a potential for patent infringement disputes or licensing negotiations.
Summary of Landscape Trends
-
The landscape is characterized by high patent density, with multiple overlapping rights.
-
Target-specific chemistry and method-of-use patents fuel competitive strategies.
-
Ongoing filings suggest continued R&D toward related compounds and indications.
Key Takeaways
-
The '533 patent presents a broad chemical and application scope, with extensive claims to compounds and methods.
-
Filing activity is concentrated among top pharma firms, with ongoing filings extending patent life.
-
Overlapping patents and patent thickets create barriers to entry and potential opposition points.
-
A global patent portfolio supports market exclusivity in key jurisdictions.
-
Future patent filings are likely to focus on derivative compounds, combination therapies, and expanded therapeutic indications.
FAQs
1. What types of claims does US Patent 10,010,533 primarily include?
The patent mainly includes chemical composition claims, method-of-treatment claims, and formulation claims related to specific compounds and their uses in disease treatment.
2. How broad are the claims in this patent?
The claims are broad within the defined chemical class, covering a spectrum of derivatives with specific core structures and substitutions, allowing flexibility but also increasing litigation risk.
3. Which companies are most active in this patent area?
Bristol-Myers Squibb, Merck, and Novartis are leading applicants, with multiple patent families covering similar compounds and therapeutic methods.
4. What are the main legal risks associated with this patent landscape?
Overlapping patents create a dense patent thicket, raising risks of infringement suits, invalidity challenges, and licensing disputes.
5. What future patent filings are expected?
Firms likely will file continuations or divisionals for related derivatives, expanded indications, and combination therapies, extending patent protection into the mid-2030s.
References
[1] USPTO Patent Database. (2023). Patent 10,010,533.
[2] Patent Landscape Reports. (2022). Oncology & Immunology Compound Patents.
[3] PatentScope. WIPO. Worldwide patent applications related to PCT filings from 2013-2020.
[4] FDA Approval Database. Therapeutic areas related to the compounds.
